PRMT5 and gastric cancer: From a database analysis, PRMT5, MEP50, and GLI1 target genes are all upregulated in known HH signaling pathway-activated cancers, including SCLC [65], gastric cancer [64], skin basal carcinoma [67], and breast cancer [68].